Faeth Therapeutics, a clinical-stage biotechnology company advancing therapies that systematically target tumor metabolism, ...
The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Asianet Newsable on MSN
Breakthrough Cancer Drug Stops Tumor Growth Safely, Protecting Healthy Cells
Researchers at the Francis Crick Institute and Vividion Therapeutics have developed a new compound that stops cancer growth ...
A breakthrough in cancer research offers new hope. Scientists have created compounds that halt tumor growth while protecting healthy cells. This experimental therapy is now entering human trials. If ...
Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick Institute and Vividion Therapeutics discovered a compound that blocks the ...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
Scientists have developed compounds that selectively block a crucial interaction between RAS and the enzyme PI3K, a driver of tumor growth. Scientists from the Francis Crick Institute and Vividion The ...
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback